Anti-EGFR aptameric construct GR20HH for controllable delivery of doxorubicin into glioblastoma cells

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

This publication describes research on a possibility of controllable delivery of doxorubicin (DOX) into glioblastoma (GB) cells, being inside non-covalent construct with anti-EGFR DNA aptamer by intercalating into artificially created duplex. The construct has been made with previously described DNA aptamer GR20 (46 nucleotides), with 3’-end 18 nucleotides extension (GR20h), which was hybridized with the complementary DNA oligonucleotides (h).

The duplex assembly is effective, the construct GR20hh is stable at 37 ºС, Tm = 59 ºС. DOX is intercalated into the construct. By applying xCelligence Real-Time Cell Analysis (RTCA) combined with self-created data processing, it has been shown that during a treatment of cell culture DOX, inside the non-covalent construct GR20hh – DOX, saves cytotoxic ability, though a kinetics of toxic action of the complex on GB cells is completely different from the kinetics of DOX along.

The unique approach and the data are the bases for a development of both a regulation and a targeting of DOX cytotoxic activity toward specific GB cells.

Full Text

Restricted Access

About the authors

B. M. Ivanov

Lomonosov Moscow State University

Author for correspondence.
Email: ivanovb661@yandex.ru

Chemistry Department

Russian Federation, Moscow

O. M. Antipova

Lomonosov Moscow State University

Email: ivanovb661@yandex.ru

Chemistry Department

Russian Federation, Moscow

Y. A. Sliman

Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia; Moscow institute of physics and technology, national research university

Email: ivanovb661@yandex.ru
Russian Federation, Moscow; Dolgoprudny

N. S. Samoylenkova

Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia

Email: ivanovb661@yandex.ru
Russian Federation, Moscow

I. N. Pronin

Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia

Email: ivanovb661@yandex.ru
Russian Federation, Moscow

G. V. Pavlova

Burdenko National Medical Research Center of Neurosurgery, Ministry of Healthcare of Russia; Institute of Higher Nervous Activity and Neurophysiology of Russian Academy of Sciences; Sechenov First Moscow State Medical University

Email: ivanovb661@yandex.ru
Russian Federation, Moscow; Moscow; Moscow

A. M. Kopylov

Lomonosov Moscow State University

Email: ivanovb661@yandex.ru

Chemistry Department

Russian Federation, Moscow

References

  1. Ai S., Duan J., Liu X., Bock S., Tian Y., Huang Z. Biological evaluation of a novel doxorubicin – peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells. Mol. Pharm. 2011. 8 (2): 375–386.
  2. Akhtar N., Mohammed H. A., Yusuf M., Al-Subaiyel A., Sulaiman G. M., Khan R. A. SPIONs conjugate supported anticancer drug doxorubicin’s delivery: current status, challenges, and prospects. Nanomaterials. 2022. 12 (20): 3686.
  3. Alieva R. R., Zavyalova E. G., Tashlitsky V. N., Kopylov A. M. Quantitative characterization of oligomeric state of G-quadruplex antithrombin aptamers by size exclusion HPLC. Mendeleev Communications. 2019. 29 (4): 424–425.
  4. Horbinski C., Berger T., Packer R. J., Wen, P. Y. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat. Rev. Neurol. 2022. 18 (9): 515–529.
  5. Kopylov A. M., Fab L. V., Antipova O., Savchenko E. A., Revishchin A. V., Parshina V. V., Pavlova S. V., Kireev I. I., Golovin A. V., Usachev D. Y., Pavlova G. V. RNA aptamers for theranostics of glioblastoma of human brain. Biochemistry (Moscow). 2021. 86: 1012–1024.
  6. Liu T., Song P., Märcher A., Kjems J., Yang C., Gothelf K. V. Selective delivery of doxorubicin to EGFR+ cancer cells by Cetuximab–DNA conjugates. Chem. Bio. Chem. 2019. 20 (8): 1014–1018.
  7. Martins‐Teixeira M.B., Carvalho I. Antitumour anthracyclines: progress and perspectives. Chem. Med. Chem. 2020. 15 (11): 933–948.
  8. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004. 56 (2): 185–229.
  9. Pérez-Arnaiz C., Busto N., Leal J. M., García B. New insights into the mechanism of the DNA/doxorubicin interaction. J. Phys. Chem B. 2014. 118 (5): 1288–1295.
  10. Pugazhendhi A., Edison T. N.J.I., Velmurugan B. K., Jacob J. A., Karuppusamy I. Toxicity of doxorubicin (Dox) to different experimental organ systems. Life Sci. 2018. 200: 26–30.
  11. Zavyalova E. G., Legatova V. A., Alieva R. S., Zalevsky A. O., Tashlitsky V. N., Arutyunyan A. M., Kopylov A. M. Putative mechanisms underlying high inhibitory activities of bimodular DNA aptamers to thrombin. Biomolecules. 2019. 9 (2): 41.
  12. Zavyalova E., Turashev A., Novoseltseva A., Legatova V., Antipova O., Savchenko E., Balk S., Golovin A., Pavlova G., Kopylov A. Pyrene-modified DNA aptamers with high affinity to wild-type EGFR and EGFRvIII. Nucl. Acid Therap. 2020. 30 (3): 175–187.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Spectrophotometric melting of the double-stranded duplex ahh (а), the GR20 aptamer (б), and the construct of the extended GR20h aptamer hybridized with complementary oligonucleotide h (в). Each graph shows the melting curves at 260 nm and their differential appearance (bottom).

Download (160KB)
Indexing metadata
3. Fig. 2. Сhromatogramm of the GR20 aptamer (red line), its extended variant GR20h (blue line), and the construction of the extended GR20h aptamer hybridized with its complementary oligonucleotide h (green line) (а) – Sensogramms of binding of the construction GR20hh with the recombinant EGFR protein (б). Scheme of interaction of immobilized aptamer construction GR20hh with protein EGFR (в).

Download (117KB)
Indexing metadata
4. Fig. 3. Fluorescence emission spectra of DOX (СDOX = 1 μМ) solution upon addition of the GR20 (а) and GR20hh construction (б). Dependence of the intensity of the DOX fluorescence maximum on the ratio of the concentrations of the oligonucleotide and DOX (в).

Download (167KB)
Indexing metadata
5. Fig. 4. Cellular index alteration for cells of the continuous GB cell culture Sus/fP2 when cells were exposed to DOX at concentrations of 0.05 μM and 1 μM (blue and blue lines) and DOX intercalated into the GR20hh complex (orange line): intact Sus/fP2 cells without exposure (gray line). Data in classical representation (а) and the same data in differentiated form, representing the rate of cell growth/death (б).

Download (120KB)
Indexing metadata
6. Fig. 5. Possible secondary structure of aptamer GR20 (a) and GR20hh construction (б).

Download (55KB)
Indexing metadata

Copyright (c) 2024 Russian Academy of Sciences

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies